Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nasdaq  >  ImmunoGen, Inc.    IMGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period June 201320142015201620172018
Sales35,559,985,575,574,672,4
Operating income (EBITDA)-68,4-66,9--101-87,2-
Operating profit (EBIT)-73,0-71,5-59,9-101-179-211
Pre-Tax Profit (EBT)-72,8-----
Net income-72,8-71,4-60,7-115-123-129
PER----10,6-10,3-10,0
EPS ( $)-0,87-0,83-0,71-1,35-1,39-1,42
Dividend per Share ( $)------
Yield------
Announcement Date08/02/2013
10:30am
08/01/2014
10:30am
07/31/2015
10:30am
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period June 201320142015201620172018
Debt----5,94-
Finance19514227883,6--
Operating income (EBITDA)-68,4-66,9--101-87,2-
Leverage
(Debt/EBITDA)
-----0,07x-
Capital Expenditure3,778,187,4310,87,885,00
Book Value Per Share (BVPS)1,44 $0,88 $0,41 $1,31 $-0,65 $-
Cash Flow per Share-0,72 $-0,63 $--1,28 $-1,29 $-
Announcement Date08/02/2013
10:30am
08/01/2014
10:30am
07/31/2015
10:30am
---
Balance Sheet Analysis
Assessed data source :
© 2015 Thomson Reuters
Advertisement
Financial Ratios

Size 2016e 2017e
Capitalization 1 242 M$ -
Entreprise Value (EV) 1 158 M$ 1 248 M$
Valuation 2016e 2017e
PER (Price / EPS)
Capitalization / Revenue 16,4x 16,6x
EV / Revenue 15,3x 16,7x
EV / EBITDA -11,5x -14,3x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 10,9x -22,0x
Profitability 2016e 2017e
Operating Margin (EBIT / Sales) -133% -239%
operating Leverage (Delta EBIT / Delta Sales) -5,79x #
Net Margin (Net Profit / Revenue) -152% -165%
ROA (Net Profit / Asset) -49,4% -
ROE (Net Profit / Equities) -73,0% -184%
Rate of Dividend - -
Balance Sheet Analysis 2016e 2017e
CAPEX / Sales   14,3% 10,6%
Cash Flow / Sales (Taux d'autofinancement) -147% -150%
Capital Intensity (Assets / Sales) 3,08x -
Financial Leverage (Net Debt / EBITDA) 0,83x -0,07x
EPS & Dividend